Organization
Utrecht University
5 abstracts
Abstract
Cost-utility analysis of a supervised exercise program for patients with metastatic breast cancer in the PREFERABLE-EFFECT randomized controlled trial (RCT).Org: University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht University, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT) Heidelberg,
Abstract
Overall survival of patients with BRAF-mutant metastatic colorectal cancer treated with encorafenib-cetuximab in a real-world nationwide study in the Netherlands.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, University Medical Center Utrecht, Utrecht University, Department of Clinical Data Science, Netherlands Comprehensive Cancer Organisation (IKNL),
Abstract
Upfront palliative resection of primary tumor versus no resection in patients with synchronous metastatic colorectal cancer: The randomized phase 3 CAIRO4 study of the Dutch Colorectal Cancer Group (DCCG).Org: University Medical Center Utrecht, Utrecht University, Netherlands Comprehensive Cancer Organisation (IKNL), Erasmus Medical Center, Amsterdam University Medical Centers,
Abstract
ASSESSMENT OF ANALGESIC TREATMENT SWITCH PATTERNS POST-ROFECOXIB WITHDRAWALOrg: Research and Development, NicOx SA, Sophia Antipolis, France, PHARMO Institute, Utrecht University, Netherlands Cancer Institute, Oncology Pain and Inflammation,
Abstract
ADALIMUMAB (HUMIRA®) IS AS EFFECTIVE WHEN USED WITH OTHER CONCOMITANT DMARDS AS WHEN USED WITH METHOTREXATE IN TREATING RHEUMATOID ARTHRITIS IN WIDESPREAD CLINICAL PRACTICE: THE REACT STUDYOrg: Bicetre Hospital, Paris XI University, Le Kremlin Bicetre, University Medical Center Utrecht, Utrecht University,